The Use Of Lithium In The Prophylaxis And Treatment Of Chemotherapy Induced Neutropenia (CIN): A Cost-Effective Option Or Hazard

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F06%3A00019207" target="_blank" >RIV/00216224:14110/06:00019207 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
The Use Of Lithium In The Prophylaxis And Treatment Of Chemotherapy Induced Neutropenia (CIN): A Cost-Effective Option Or Hazard
Original language description
Introduction: Lithium is an antimanic agent successfully used in the treatment of patients with bipolar disorder. Even at therapeutic levels many patients experience one of the most frequent non-toxic and reversible side effect of lithium: leukocytosis.Due this effect, lithium has been used in the treatment and prophylaxis of CIN before the availability of colony-stimulating factors (CSF) and it remains as a costeffective option compared with CSF. Recently, lithium has been reported to protect cells against apoptosis via a direct inhibition of GSK-3beta and activation of Akt/PKB. Both kinases play important role in processes of primary and inducible tumor chemoresistance. Results: I. 151 MTT tests were performed for in-vitro testing of chemo-sensitivity of 53 primary tumours against cisplatin, melphalan, doxorubicin and paclitaxel with or without presence of 10mM or 2mM lithium. At the concentration of 10mM, lithium enormously increased chemoresistance of primary tumours against doxor
Czech name
Použití lithia k profylaxi a léčbě chemoterapií indukované neutropenie: efektivní postup nebo hazard?
Czech description
Práce je pouze v anglickém jazyce.

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Project
<a href="/en/project/NR8335" target="_blank" >NR8335: Prediction of chemosensitivity / chemoresistance to the target therapy of breast carcinoma with amplification of the Her-2 gene, based on the analysis of Akt signal pathway and serial quantitative testing for serum HER-2/neu extracellular domain</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2006
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)